Ajanta Pharma Ltd: Valuation Shift Signals Price Attractiveness Amid Strong Returns

Valuation Metrics and Recent Grade Change

As of 24 August 2026, Ajanta Pharma’s price-to-earnings (P/E) ratio stands at 40.22, a figure that, while still elevated, represents a moderation from previous levels that classified the stock as very expensive. The price-to-book value (P/BV) ratio is currently 10.08, underscoring the premium investors are willing to pay for the company’s equity relative to its book value. Other valuation multiples include an enterprise value to EBIT (EV/EBIT) of 35.05 and an EV to EBITDA of 30.84, both indicative of a richly valued stock but showing signs of relative easing.

These valuation metrics have prompted MarketsMOJO to upgrade Ajanta Pharma’s mojo grade from 'Hold' to 'Buy' on 23 March 2026, reflecting improved confidence in the company’s growth prospects and financial health. The mojo score currently stands at a robust 72.0, signalling a favourable outlook supported by strong fundamentals.

Comparative Analysis with Industry Peers

When benchmarked against key competitors within the Pharmaceuticals & Biotechnology sector, Ajanta Pharma’s valuation remains on the higher side but is more reasonable than some peers. For instance, Laurus Labs is classified as 'very expensive' with a P/E ratio of 89.67 and an EV/EBITDA of 49.39, while Mankind Pharma is also 'expensive' with a P/E of 45.59. Conversely, companies like Lupin and Zydus Lifesciences are deemed 'very attractive' and 'attractive' respectively, with Lupin’s P/E at 16.82 and Zydus Lifesciences at 22.65, highlighting a significant valuation gap.

Ajanta Pharma’s PEG ratio of 1.83, which adjusts the P/E for earnings growth, is moderate compared to Mankind Pharma’s 3.39 and Laurus Labs’ 0.78, suggesting a balanced growth-to-valuation trade-off. This positions Ajanta Pharma as a stock that, while expensive, offers a more sustainable valuation relative to its growth trajectory than some of its pricier peers.

Financial Performance and Return Analysis

Ajanta Pharma’s financial metrics underpin its valuation. The company boasts a return on capital employed (ROCE) of 29.63% and a return on equity (ROE) of 23.33%, both indicative of efficient capital utilisation and strong profitability. Its dividend yield, while modest at 1.64%, complements its growth orientation.

Stock price performance relative to the broader market has been impressive. Year-to-date (YTD), Ajanta Pharma has delivered a 31.41% return compared to the Sensex’s negative 9.01%. Over one year, the stock has appreciated by 37.07%, significantly outperforming the Sensex’s decline of 5.44%. Longer-term returns are even more compelling, with a three-year gain of 103.39% versus the Sensex’s 18.90%, and a five-year return of 144.30% compared to the Sensex’s 40.14%. Over a decade, Ajanta Pharma’s 177.09% return closely matches the Sensex’s 176.17%, underscoring sustained value creation.

Price Movement and Market Capitalisation

On 24 August 2026, Ajanta Pharma’s stock closed at ₹3,640.35, down marginally by 0.69% from the previous close of ₹3,665.65. The day’s trading range was between ₹3,624.80 and ₹3,715.65, with the 52-week high at ₹3,796.95 and a low of ₹2,335.00. The company is classified as a mid-cap stock, reflecting its market capitalisation and growth potential within the sector.

Despite the slight dip on the day, the stock’s valuation grade shift from very expensive to expensive suggests a more attractive entry point for investors who had previously been deterred by its premium multiples. This re-rating aligns with the company’s consistent earnings growth and solid return ratios.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector remains a focal point for investors seeking growth and defensive qualities amid global economic uncertainties. Ajanta Pharma’s valuation adjustment comes at a time when peers exhibit a wide range of price-to-earnings and enterprise value multiples, reflecting diverse growth prospects and risk profiles.

While some competitors like Laurus Labs command extremely high valuations, Ajanta Pharma’s more moderate expensive rating, combined with its strong fundamentals and mojo grade upgrade, positions it favourably for investors prioritising quality mid-cap stocks with growth visibility.

Investment Implications and Outlook

Ajanta Pharma’s recent valuation grade upgrade to 'Buy' by MarketsMOJO reflects a growing consensus that the stock’s price now better aligns with its earnings growth and capital efficiency. The shift from very expensive to expensive valuation territory signals a potential correction in investor sentiment, making the stock more accessible without compromising on quality.

Investors should weigh Ajanta Pharma’s premium multiples against its strong return ratios and consistent outperformance relative to the Sensex. While the P/E ratio remains elevated compared to some peers, the company’s solid ROCE and ROE, alongside a reasonable PEG ratio, suggest that the valuation premium is justified by growth prospects and operational efficiency.

Given the competitive landscape, Ajanta Pharma’s mid-cap status and mojo score of 72.0 position it as a compelling candidate for portfolios seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk-reward profile. However, investors should remain mindful of sector volatility and monitor valuation trends relative to earnings momentum.

Conclusion

Ajanta Pharma Ltd.’s valuation adjustment from very expensive to expensive marks a significant development in its market narrative. Supported by strong financial metrics, robust returns, and a favourable mojo grade upgrade, the stock presents a more attractive proposition for investors seeking quality mid-cap exposure in the pharmaceutical space. While valuation remains on the higher side, the company’s growth fundamentals and relative peer positioning justify a positive outlook, making Ajanta Pharma a noteworthy consideration for discerning investors.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →